The novel use of very high doses of cabergoline and a combination of testosterone and an aromatase inhibitor in the treatment of a giant prolactinoma

Journal of Clinical Endocrinology and Metabolism

Volumn 87, Issue 10, 2002, Pages 4447-4451

  Gillam, Mary P ^a   Middler, Stewart ^b   Freed, Daniel J ^a   Molitch, Mark E ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; CABERGOLINE; DOPAMINE RECEPTOR STIMULATING AGENT; ESTRADIOL; PROLACTIN; TESTOSTERONE;

ADULT; AROMATIZATION; ARTICLE; CASE REPORT; DRUG MEGADOSE; DRUG USE; HORMONE SUBSTITUTION; HUMAN; HYPERPROLACTINEMIA; HYPOGONADISM; INJECTION; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; PROLACTIN RELEASE; PROLACTINOMA; SEXUAL FUNCTION; SIDE EFFECT; TESTOSTERONE BLOOD LEVEL; TESTOSTERONE SYNTHESIS;

ADULT; AROMATASE INHIBITORS; BROMOCRIPTINE; DOPAMINE AGONISTS; ENZYME INHIBITORS; ERGOLINES; HORMONE REPLACEMENT THERAPY; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; NITRILES; PITUITARY NEOPLASMS; PROLACTIN; PROLACTINOMA; SEXUAL DYSFUNCTION, PHYSIOLOGICAL; TESTOSTERONE; TREATMENT OUTCOME; TRIAZOLES;

EID: 0036774377     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.2002-020426     Document Type: Article

References (31)

1. Verhelst J, Abs R, Maiter D, van den Bruel A, Vandeweghe M, Velkeniers B, Mockel J, Lamberigts G, Petrossians P, Coremans P, Mahler C, Stevenaert A, Verlooy J, Raftopoulos C, Beckers A 1999 Cabergoline in the treatment of hyperprolactinemia: A study in 455 patients. J Clin Endocrinol Metab 84:2518-2522
2. Biller BM, Molitch ME, Vance ML, Cannistraro KB, Davis KR, Simons JA, Schoenfelder JR, Klibanski A 1996 Treatment of prolactin-secreting macroadenomas with the once-weekly dopamine agonist cabergoline. J Clin Endocrinol Metab 81:2338-2343
3. Colao A, Di Sarno A, Landi ML, Cirillo S, Sarnacchiaro F, Facciolli G, Pivonello R, Cataldi M, Merola B, Annunziato L, Lombardi G 1997 Long-term and low-dose treatment with cabergoline induces macroprolactinoma shrinkage. J Clin Endocrinol Metab 82:3574-3579
4. Molitch ME 2001 Disorders of prolactin secretion. Endocrinol Metab Clin North Am 30:585-610
5. Bevan JS, Webster J, Burke CW, Scanlon MF 1992 Dopamine agonists and pituitary tumor shrinkage. Endocr Rev 13:220-240
6. Di Sarno A, Landi ML, Cappabianca P, Di Salle F, Rossi FW, Pivonello R, Di Somma C, Faggiano A, Lombardi G, Colao A 2001 Resistance to cabergoline as compared with bromocriptine in hyperprolactinemia: Prevalence, clinical definition, and therapeutic strategy. J Clin Endocrinol Metab 86:5256-5261
7. Colao A, Di Sarno A, Sarnacchiaro F, Ferone D, Di Renzo G, Merola B, Annunziato L, Lombardi G 1997 Prolactinomas resistant to standard dopamine agonists respond to chronic cabergoline treatment. J Clin Endocrinol Metab 82:876-883
8. Molitch ME, Elton RL, Blackwell RE, Caldwell B, Chang RJ, Jaffe R, Joplin G, Robbins RJ, Tyson J, Thorner MO 1985 Bromocriptine as primary therapy for prolactin-secreting macroadenomas: Results of a prospective multicenter study. J Clin Endocrinol Metab 60:698-705
9. Pinzone JJ, Katznelson L, Danila DC, Pauler DK, Miller CS, Klibanski A 2000 Primary medical therapy of micro- and macroprolactinomas in men. J Clin Endocrinol Metab 85:3053-3057
10. Carter JN, Tyson JE, Tolis G, Van Vliet S, Faiman C, Friesen HG 1978 Prolactin-screening tumors and hypogonadism in 22 men. N Engl J Med 299:847-852
11. Murray FT, Cameron DF, Ketchum C 1984 Return of gonadal function in men with prolactin-secreting pituitary tumors. J Clin Endocrinol Metab 59:79-85
12. Lera G, Vaamonde J, Rodriguez M, Obeso JA 1993 Cabergoline in Parkinson's disease: Long-term follow-up. Neurology 43:2587-2590
13. Hutton JT, Koller WC, Ahlskog JE, Pahwa R, Hurtig HI, Stern MB, Hiner BC, Lieberman A, Pfeiffer RF, Rodnitzky RL, Waters CH, Muenter MD, Adler CH, Morris JL 1996 Multicenter, placebo-controlled trial of cabergoline taken once daily in the treatment of Parkinson's disease. Neurology 46:1062-1065
14. Heaney AP, Fernando M, Melmed S 2002 Functional role of estrogen in pituitary tumor pathogenesis. J Clin Invest 109:277-283
15. Munemura M, Agui T, Sibley DR 1989 Chronic estrogen treatment promotes a functional uncoupling of the D2 dopamine receptor in rat anterior pituitary gland. Endocrinology 124:346-355
16. Gooren LJ, van der Veen EA, van Kessel H, Harmsen-Louman W, Wiegel AR 1984 Prolactin secretion in the human male is increased by endogenous oestrogens and decreased by exogenous/endogenous androgens. Int J Androl 7:53-60
17. Maurer RA 1982 Relationship between estradiol, ergocryptine, and thyroid hormone: Effects on prolactin synthesis and prolactin messenger ribonucleic acid levels. Endocrinology 110:1515-1520
18. Raymond V, Beaulieu M, Labrie F, Boissier J 1978 Potent antidopaminergic activity of estradiol at the pituitary level on prolactin release. Science 200:1173-1175
19. West B, Dannies PS 1980 Effects of estradiol on prolactin production and dihydroergocryptine-induced inhibition of prolactin production in primary cultures of rat pituitary cells. Endocrinology 106:1108-1113
20. Seyfred MA, Kladde MP, Gorski J 1989 Transcriptional regulation by estrogen of episomal prolactin gene regulatory elements. Mol Endocrinol 3:305-314
21. Gooren LJ, Assies J, Asscheman H, de Slegte R, van Kessel H 1988 Estrogen-induced prolactinoma in a man. J Clin Endocrinol Metab 66:444-446
22. Kovacs K, Stefaneanu L, Ezzat S, Smyth HS 1994 Prolactin-producing pituitary adenoma in a male-to-female transsexual patient with protracted estrogen administration. A morphologic study. Arch Pathol Lab Med 118:562-565
23. Serri O, Noiseux D, Robert F, Hardy J 1996 Lactotroph hyperplasia in an estrogen treated male-to-female transsexual patient. J Clin Endocrinol Metab 81:3177-3179
24. Prior JC, Cox TA, Fairholm D, Kostashuk E, Nugent R 1987 Testosterone-related exacerbation of a prolactin-producing macroadenoma: Possible role for estrogen. J Clin Endocrinol Metab 64:391-394
25. Finkelstein JS, Whitcomb RW, O'Dea LS, Longcope C, Schoenfeld DA, Crowley Jr WF 1991 Sex steroid control of gonadotropin secretion in the human male. I. Effects of testosterone administration in normal and gonadotropin-releasing hormone-deficient men. J Clin Endocrinol Metab 73:609-620
26. Finkelstein JS, O'Dea LS, Whitcomb RW, Crowley Jr WF 1991 Sex steroid control of gonadotropin secretion in the human male. II. Effects of estradiol administration in normal and gonadotropin-releasing hormone-deficient men. J Clin Endocrinol Metab 73:621-628
27. Bagatell CJ, Dahl KD, Bremner WJ 1994 The direct pituitary effect of testosterone to inhibit gonadotropin secretion in men is partially mediated by aromatization to estradiol. J Androl 15:15-21
28. Hayes FJ, Seminara SB, Decruz S, Boepple PA, Crowley Jr WF 2000 Aromatase inhibition in the human male reveals a hypothalamic site of estrogen feedback. J Clin Endocrinol Metab 85:3027-3035
29. Schnorr JA, Bray MJ, Veldhuis JD 2001 Aromatization mediates testosterone's short-term feedback restraint of 24-hour endogenously driven and acute exogenous gonadotropin-releasing hormone-stimulated luteinizing hormone and follicle-stimulating hormone secretion in young men. J Clin Endocrinol Metab 86:2600-2606
30. Mauras N, O'Brien KO, Klein KO, Hayes V 2000 Estrogen suppression in males: Metabolic effects. J Clin Endocrinol Metab 85:2370-2377
31. Grumbach MM, Auchus RJ 1999 Estrogen: Consequences and implications of human mutations in synthesis and action. J Clin Endocrinol Metab 84:4677-4694